

Raffit Hassan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4316748/publications.pdf>

Version: 2024-02-01

122
papers

10,193
citations

31976

53
h-index

34986

98
g-index

122
all docs

122
docs citations

122
times ranked

8411
citing authors

#	ARTICLE	IF	CITATIONS
1	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	10.7	25
2	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
3	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	4.1	18
4	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2202439119.	7.1	8
5	Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies. <i>Cancer</i> , 2021, 127, 1010-1020.	4.1	15
6	<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 316-325.	1.0	9
7	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	1.1	16
8	Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 457-461.	1.1	24
9	Response to Letter to the Editor by Yang et al.. <i>Journal of Thoracic Oncology</i> , 2020, 15, e91.	1.1	0
10	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
11	Response to Letter to Editor by Cornelissen et al.. <i>Journal of Thoracic Oncology</i> , 2020, 15, e169-e170.	1.1	0
12	Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. <i>Frontiers in Oncology</i> , 2020, 10, 343.	2.8	48
13	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1824-1835.	1.6	102
14	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	28
15	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	1.1	51
16	¹⁸ F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1570-1575.	5.0	4
17	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5787-5798.	7.0	72
18	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108

#	ARTICLE	IF	CITATIONS
19	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.9	97
20	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	7.1	127
21	Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9093-9093.	1.6	2
22	CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 622-630.	3.4	9
23	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2859-2872.	7.0	40
24	Malignant Mesothelioma. , 2018, , 536-549.e4.		0
25	Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. <i>Human Pathology</i> , 2018, 71, 1-7.	2.0	46
26	Reply to D. de Fonseca et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2746-2747.	1.6	0
27	Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-16.	3.0	6
28	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
29	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 166-177.	1.3	6
30	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	1.1	87
31	Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8504-8504.	1.6	8
32	Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8563-8563.	1.6	4
33	Targeting mesothelin in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 36050-36051.	1.8	10
34	Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e871-e875.	1.9	4
35	Immunotherapeutic Approaches to Mesothelioma. <i>Current Cancer Research</i> , 2017, , 347-357.	0.2	0
36	CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?. <i>Lancet Oncology, The</i> , 2017, 18, 1150-1151.	10.7	4

#	ARTICLE	IF	CITATIONS
37	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. <i>Clinical Cancer Research</i> , 2017, 23, 1564-1574.	7.0	32
38	A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2511-2511.	1.6	6
39	Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 26744-26754.	1.8	38
40	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. <i>Oncotarget</i> , 2017, 8, 87307-87316.	1.8	14
41	Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 246-252.	1.2	12
42	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016, 101, 104-110.	2.0	18
43	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4171-4179.	1.6	244
44	Consensus Report of the 2015 Weinman International Conference on Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1246-1262.	1.1	122
45	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1993-2005.	1.1	96
46	Antibody-drug conjugates for cancer therapy. <i>Lancet Oncology</i> , The, 2016, 17, e254-e262.	10.7	439
47	Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 733-743.	2.3	16
48	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	7.0	38
49	Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2509-2509.	1.6	25
50	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8503-8503.	1.6	43
51	CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8558-8558.	1.6	2
52	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. <i>Oncotarget</i> , 2016, 7, 29916-29926.	1.8	41
53	Advances in Anticancer Immunotoxin Therapy. <i>Oncologist</i> , 2015, 20, 176-185.	3.7	161
54	New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma. <i>Scientific Reports</i> , 2015, 5, 9928.	3.3	37

#	ARTICLE	IF	CITATIONS
55	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. <i>BMC Cancer</i> , 2015, 15, 376.	2.6	22
56	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2789-2796.	4.1	34
57	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8034-8034.	1.6	59
58	Safety and biodistribution of ¹¹¹ In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	1.8	38
59	High mesothelin expression in advanced lung adenocarcinoma is associated with <i>KRAS</i> mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	1.8	66
60	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2014, 20, 5927-5936.	7.0	158
61	Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. <i>Cancer Research</i> , 2014, 74, 2907-2912.	0.9	204
62	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8571-8576.	7.1	104
63	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. <i>Cancer</i> , 2014, 120, 3311-3319.	4.1	144
64	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. <i>Gastroenterology</i> , 2014, 146, 1784-1794.e6.	1.3	118
65	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. <i>PLoS ONE</i> , 2014, 9, e104388.	2.5	8
66	New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. <i>American Journal of Pathology</i> , 2013, 182, 1065-1077.	3.8	91
67	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. <i>Science Translational Medicine</i> , 2013, 5, 208ra147.	12.4	198
68	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 48-57.	4.1	87
69	A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. <i>Clinical Cancer Research</i> , 2012, 18, 858-868.	7.0	304
70	Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 721-5.	2.3	15
71	Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. <i>Oncology Reports</i> , 2012, 27, 1794-800.	2.6	10
72	Immunotherapies for non-small-cell lung cancer and mesothelioma. <i>Lancet Oncology</i> , The, 2012, 13, e301-e310.	10.7	99

#	ARTICLE	IF	CITATIONS
73	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11782-11787.	7.1	145
74	Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Molecular Cancer Therapeutics, 2012, 11, 517-525.	4.1	96
75	Efficacy of anti- α insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor α 1 receptor sites/cell. International Journal of Cancer, 2012, 131, 2143-2152.	5.1	20
76	Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.. Journal of Clinical Oncology, 2012, 30, 7030-7030.	1.6	10
77	Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Research, 2012, 32, 5151-8.	1.1	18
78	Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 2011, 73, 256-263.	2.0	55
79	Effect of chelator conjugation level and injection dose on tumor and organ uptake of ^{111}In -labeled MORAb-009, an anti-mesothelin antibody. Nuclear Medicine and Biology, 2011, 38, 1119-1127.	0.6	28
80	The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy. PLoS ONE, 2011, 6, e14640.	2.5	42
81	In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice. Journal of Cancer, 2011, 2, 123-131.	2.5	19
82	Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. Clinical Cancer Research, 2011, 17, 3697-3705.	7.0	44
83	Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding. Cancer Research, 2011, 71, 5915-5922.	0.9	31
84	Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin. Cancer Immunology, Immunotherapy, 2010, 59, 737-746.	4.2	17
85	Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research, 2010, 16, 6132-6138.	7.0	190
86	Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer, 2010, 68, 455-459.	2.0	67
87	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake. Cancer Research, 2010, 70, 1082-1089.	0.9	38
88	A Binding Domain on Mesothelin for CA125/MUC16. Journal of Biological Chemistry, 2009, 284, 3739-3749.	3.4	142
89	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. Clinical Cancer Research, 2009, 15, 5274-5279.	7.0	209
90	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3360-3365.	7.1	758

#	ARTICLE	IF	CITATIONS
91	Mesothelin targeted cancer immunotherapy. <i>European Journal of Cancer</i> , 2008, 44, 46-53.	2.8	288
92	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17099-17104.	7.1	75
93	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 5144-5149.	7.0	351
94	Mesothelin Expression in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1571-1575.	7.0	118
95	Immunotoxin Treatment of Cancer*. <i>Annual Review of Medicine</i> , 2007, 58, 221-237.	12.2	340
96	Anti-Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts. <i>Clinical Cancer Research</i> , 2007, 13, 7166-7171.	7.0	60
97	Releasable PEGylation of Mesothelin Targeted Immunotoxin SS1P Achieves Single Dosage Complete Regression of a Human Carcinoma in Mice. <i>Bioconjugate Chemistry</i> , 2007, 18, 773-784.	3.6	40
98	Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. <i>European Journal of Haematology</i> , 2007, 79, 281-286.	2.2	29
99	Advances in diffuse malignant peritoneal mesothelioma. <i>Oncology Reviews</i> , 2007, 1, 53-64.	1.8	5
100	Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. <i>Cancer Immunity</i> , 2007, 7, 20.	3.2	127
101	Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 447-453.	7.0	256
102	Immunotoxin therapy of cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 559-565.	28.4	475
103	Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts. <i>Clinical Cancer Research</i> , 2006, 12, 4983-4988.	7.0	43
104	Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 4225-4231.	7.0	101
105	Mesothelin Is Shed from Tumor Cells: Figure 1.. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1751-1751.	2.5	55
106	Characterization of the B Cell Epitopes Associated with a Truncated Form of <i>Pseudomonas</i> Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. <i>Journal of Immunology</i> , 2006, 177, 8822-8834.	0.8	104
107	Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice. <i>Clinical Cancer Research</i> , 2006, 12, 4695-4701.	7.0	73
108	Localization of Mesothelin in Epithelial Ovarian Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 243-247.	1.2	152

#	ARTICLE	IF	CITATIONS
109	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. <i>Clinical Cancer Research</i> , 2005, 11, 5840-5846.	7.0	65
110	Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 3814-3820.	7.0	140
111	Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic Pancreatitis. <i>American Journal of Clinical Pathology</i> , 2005, 124, 838-845.	0.7	197
112	Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin. <i>Clinical Cancer Research</i> , 2005, 11, 6342-6351.	7.0	56
113	Nonpleural Mesotheliomas: Mesothelioma of the Peritoneum, Tunica Vaginalis, and Pericardium. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 1067-1087.	2.2	45
114	Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1201-9.	5.0	26
115	Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. <i>American Journal of Clinical Pathology</i> , 2005, 124, 838-45.	0.7	114
116	Mesothelin. <i>Clinical Cancer Research</i> , 2004, 10, 3937-3942.	7.0	394
117	Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. <i>Clinical Cancer Research</i> , 2004, 10, 16-18.	7.0	51
118	Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. <i>Anticancer Research</i> , 2004, 24, 1327-35.	1.1	42
119	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. <i>Clinical Cancer Research</i> , 2002, 8, 3520-6.	7.0	60
120	Ex Vivo Cytokine Activation of Peripheral Blood Stem Cells: A Potential Role for Adoptive Cellular Immunotherapy. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 283-290.	1.8	8
121	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. <i>Journal of Immunotherapy</i> , 2000, 23, 473-479.	2.4	60
122	111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33